Your browser doesn't support javascript.
loading
Qualitative Study of User Experiences with Loop, an Open-Source Automated Insulin Delivery System.
Suttiratana, Sakinah C; Wong, Jessie J; Lanning, Monica S; Dunlap, Adrienne; Hanes, Sarah J; Hood, Korey K; Lal, Rayhan A; Naranjo, Diana.
Afiliação
  • Suttiratana SC; Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
  • Wong JJ; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Lanning MS; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Dunlap A; Division of Agriculture, Food, and Environment, Tufts University, Friedman School of Nutrition Science and Policy, Medford, Massachusetts, USA.
  • Hanes SJ; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Hood KK; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
  • Lal RA; Stanford Diabetes Research Center (SDRC), Stanford University School of Medicine, Stanford, California, USA.
  • Naranjo D; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, USA.
Diabetes Technol Ther ; 24(6): 416-423, 2022 06.
Article em En | MEDLINE | ID: mdl-35099278
Background: Loop is an open-source automated insulin delivery (AID) system, used by more than 9,000 people with type 1 diabetes. Understanding the pros and cons of Loop use may help improve disease management and support population level innovation. Methods: Focus groups revealed 72 new and existing users' perspectives on Loop uptake, use, and persistence. A subsample of participants from a mixed-methods, observational cohort study shared first-hand accounts of their experiences using Loop. Participants were predominately white (95%), male (50%), privately insured (94%), and reported annual household income ≥$100K (73%) and education exceeding a bachelor's degree (87%) with a mean HbA1c of 6.6% ± 0.8%. Data were analyzed and synthesized by a multidisciplinary team. Results: Participants detailed their experiences with (1) Loop technical support and troubleshooting, (2) decreased mental/behavioral burden, (3) technical issues with parts of the system, (4) glycemic control, (5) personalizing settings, and (6) providers while using Loop. Decreased burden was the most endorsed benefit defined by less worry, stress, and cognitive effort and less time spent on diabetes management tasks. Participants highlighted the benefits of Loop overnight and their introduction to "Loop communities" during use. The most discussed challenges involved technical issues. A range of provider attitudes and knowledge about Loop complicated users' clinical experiences and disclosure. Conclusions: This sample of new and experienced Loop users reported benefits to quality of life and glycemic control that outweighed challenges of setting up system components, customizing the system to suit one's lifestyle and habits, and adjusting system settings. Challenges related to system setup and calibrating settings are remediable and, if addressed, may better serve Loop users. Users reported feeling empowered by the customizability of and the educational effects facilitated by the open-source AID system. Loop helped users learn more about their chronic illness and physiology in an acceptable format. Clinical Trial Registration number: NCT03838900.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pâncreas Artificial / Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Observational_studies / Qualitative_research Limite: Humans / Male Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pâncreas Artificial / Diabetes Mellitus Tipo 1 Tipo de estudo: Clinical_trials / Observational_studies / Qualitative_research Limite: Humans / Male Idioma: En Revista: Diabetes Technol Ther Assunto da revista: ENDOCRINOLOGIA / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos